NKTR Nektar Therapeutics

13.10
+0.12  (0.92%)
Previous Close 12.98
Open 12.90
Price To book 0.00
Market Cap 2.00B
Shares 152,835,000
Volume 1,457,495
Short Ratio 8.34
Av. Daily Volume 1,173,460

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due 1H 2017.
Cipro DPI
Bronchiectasis
Approved November 16 2015
ADYNOVATE
Hemophilia A
Approved Sept 16 2014
MOVANTIK (Naloxegol)
Opioid-induced constipation (OIC)
Phase 3 topline data mid March 2015 did not reach primary endpoint
Etirinotecan pegol NKTR-102 (BEACON)
Cancer - Metastatic Breast Cancer
Data due March 2017.
NKTR-181
Lower back pain
Phase 1/2 ongoing. Initial data due 1H 2017.
NKTR-214
Solid tumors - cancer
Phase 3 data due June/July 2017.
Inhaled Amikacin Solution (BAY41-6551T)
Gram-Negative Pneumonia (INHALE 1)
Phase 3 data released December 12, 2016 - primary endpoint not met.
Fovista
Wet-AMD

Latest News

  1. 2:28 am Nektar Therapeutics reports Phase 1 dose-escalation study of single-agent NKTR-214 indicating encouraging anti-tumor activity
  2. Clinical Data from Phase 1 Dose-Escalation Study of Single-Agent NKTR-214 in Patients with Renal Cell Carcinoma Presented at the ASCO 2017 Genitourinary Cancers Symposium
  3. Biotech Industry a Focus in 2017: Latest Reports on Nektar Therapeutics and Acasti Pharma
  4. Benzinga's Option Alert Recap From January 23
  5. NEKTAR THERAPEUTICS Files SEC form 8-K, Results of Operations and Financial Condition, Other Events
  6. Nektar Therapeutics – Value Analysis (NASDAQ:NKTR) : January 6, 2017
  7. Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco, CA
  8. Nektar Therapeutics breached its 50 day moving average in a Bullish Manner : NKTR-US : January 5, 2017
  9. ETFs with exposure to Nektar Therapeutics : December 27, 2016
  10. Shire Announces FDA Approval of Adynovate® for use in Children and Surgical Settings
  11. ETFs with exposure to Nektar Therapeutics : December 16, 2016
  12. These small-cap stocks are expected to rise at least 31% in 2017
  13. ETFs with exposure to Nektar Therapeutics : December 6, 2016
  14. Is The New York Times Co (NYT) A Good Stock To Buy?
  15. ETFs with exposure to Nektar Therapeutics : November 14, 2016
  16. Nektar Therapeutics to Present at Jefferies 2016 Global Healthcare Conference in London
  17. NEKTAR THERAPEUTICS Financials
  18. Nektar Therapeutics :NKTR-US: Earnings Analysis: Q3, 2016 By the Numbers : November 10, 2016
  19. Nektar Therapeutics Presents New Clinical Data from Ongoing Phase 1 Dose-Escalation Study of NKTR-214 at the Society for Immunotherapy of Cancer (SITC) 2016 Annual Meeting
  20. NEKTAR THERAPEUTICS Files SEC form 8-K, Other Events
  21. Nektar (NKTR) Stock Up on Narrower-than-Expected Q3 Loss
  22. Cormorant Asset Management’s Bets on Alder Biopharmaceuticals Inc (ALDR) and Other Healthcare Stocks Show Strong Returns
  23. Nektar to Announce Financial Results for the Third Quarter 2016 on Thursday, November 3, 2016, After Close of U.S.-Based Financial Markets
  24. Bristol-Myers Squibb and Nektar Therapeutics Announce Oncology Clinical Collaboration to Evaluate the Combination of Opdivo (nivolumab) and NKTR-214
  25. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2016
  26. Nektar to Announce Financial Results for the Second Quarter 2016 on Wednesday, August 3, 2016, After Close of U.S.-Based Financial Markets
  27. Preclinical Data Presented at ASCO 2016 Annual Meeting Demonstrate that Single-Agent NKTR-214 Produces a Large Increase in Tumor-Infiltrating Lymphocytes to Provide Durable Anti-Tumor Activity
  28. Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the Jefferies 2016 Global Healthcare Conference in New York City
  29. Nektar Therapeutics Announces Executive Management Promotions
  30. Nektar Therapeutics and Daiichi Sankyo Europe GmbH Sign European Licensing Agreement for ONZEALD™ (etirinotecan pegol), an Investigational Drug Candidate Being Developed to Treat Patients with Advanced Breast Cancer and Brain Metastases
  31. Nektar Therapeutics Reports Financial Results for the First Quarter of 2016
  32. Nektar to Announce Financial Results for the First Quarter 2016 on Tuesday, May 3, 2016, After Close of U.S.-Based Financial Markets
  33. Preclinical Data Presented at AACR Demonstrate that Combining NKTR-214 with Checkpoint Blockade is Superior to Dual Checkpoint Inhibition in Increasing Clonality of the T Cell Receptor (TCR) Repertoire and T Cell Tumor Infiltration